Antiviral therapy

Abstract

The invention relates to the field of antiviral agents, and more specifically to antiviral therapy. The invention provides use of at least one compound or mixture of compounds of the general formula or a functional equivalent or pharmaceutically acceptable salt or hydrate thereof for the production of a pharmaceutical composition for the treatment of a viral infection.

1 . A method for treating a viral infection in a subject suffering therefrom with a first antiviral agent, the viral infection caused by a virus at least partially resistant to a second antiviral agent, said method comprising: administering to the subject the first antiviral agent wherein said first antiviral agent comprises a compound or a pharmaceutically acceptable salt or hydrate thereof, wherein said compound is of the general formula  
       
         
           
           
               
               
           
         
       
       and  
       wherein X and Y are independently selected from the group consisting of O, S, SO, SO 2 , and  
       SO 3 ; wherein n is 0, 1, 2, 3, 4;  
       wherein R, R′ are independently H with the proviso that when R is H, R′ is not H, a C 1 -C 10 , branched or unbranched, substituted or unsubstituted (preferably the substitute is one or more of halogen or CF 3 ), saturated or (poly)unsaturated, (cyclo)alkyl, alkene, alkyn, (cyclo)aryl, aryl(cyclo)alkyl, (cyclo)alkylaryl, alkoxyaryl, alkoxyalkene, alkoxyalkyne, enyne, diene, diyne or alkoxyalkyl, preferably selected from the group consisting of H, CH 3 , CF 3 , CH 2 Cl, CH 2 Br, CH 2 CH 3 , (CH 2 ) 2 CH 3 , (CH 2 ) 3 CH 3 , (CH 2 ) 4 CH 3 , (CH 2 ) 5 CH 3 , (CH 2 ) 6 CH 3 , CH(CH 3 ) 2 , CH(CH 3 ) 3 , CH═C═CH 2 , (CH 2 ) 2 O(CH 2 ) 3 CH 3 , CH 2 HC═CH(CH 2 ) 3 CH 3 , CH 2 C═C(CH 2 ) 3 CH 3 , CH 2 C═C(CH 2 ) 2 CH 3 , CH 2 C═C—CCH 2 CH 3 , CH 2 C═C—CH 3  and CH 2 C═CH and isomers or homologues thereof; and 
 Z is independently R, R′, XR, XR′, YR or YR′ or a functional equivalent thereof.  
 
     
     
         2 . The method according to  claim 1  wherein the viral infection is of retroviral origin.  
     
     
         3 . The method according to  claim 1  wherein the viral infection is caused by a virus at least partially resistant to treatment with an antiviral agent selected from the group of reverse transcriptase inhibitors and protease inhibitors.  
     
     
         4 . The method according to  claim 1  further comprising administering to the subject another pharmaceutical composition.  
     
     
         5 . The method according to  claim 2  further comprising administering to the subject another pharmaceutical composition.  
     
     
         6 . The method according to  claim 3  further comprising administering to the subject another pharmaceutical composition.  
     
     
         7 . The method according to  claim 4  wherein the other pharmaceutical composition comprises an antiviral agent.  
     
     
         8 . The method according to  claim 5  wherein the other pharmaceutical composition comprises an antiviral agent.  
     
     
         9 . The method according to  claim 6  wherein the other pharmaceutical composition comprises an antiviral agent.  
     
     
         10 . A method of treating a viral infection in a subject suffering therefrom with a first antiviral agent, said viral infection caused by a virus that is at least partly resistant to a second antiviral agent, said method comprising administering to the subject said first antiviral agent wherein said first antiviral agent comprises a compound or a pharmaceutically acceptable salt or hydrate thereof, wherein said compound is of the general formula  
       
         
           
           
               
               
           
         
       
       or a functional equivalent thereof, wherein R is selected from the group consisting of H, CH 3 , CH 2 CH 3 , (CH 2 ) 2 CH 3 , (CH 2 ) 3 CH 3 , (CH 2 ) 4 CH 3 , (CH 2 ) 5 CH 3 , (CH 2 ) 6 CH 3 , CH(CH 3 ) 2 , CH(CH 3 ) 3 , CH═C═CH 2 , (CH 2 ) 2 O(CH 2 ) 3 CH 3 , CH 2 HC═CH(CH 2 ) 3 CH 3 , CH 2 C═C(CH 2 ) 3 CH 3 , CCH 2 C═C(CH 2 ) 2 CH 3 , CH 2 C═C—CCH 2 CH 3 , CH 2 C═C—CH 3  and CH 2 C═CH and isomers or homologues thereof, and R′ is selected from the group consisting of H, CH 3 , CF 3 , CH 2 CL and CH 2 Br.  
     
     
         11 . The method according to  claim 10  wherein the viral infection is of retroviral origin.  
     
     
         12 . The method according to  claim 10  wherein the viral infection is caused by a virus at least partially resistant to treatment with an antiviral agent selected from the group of reverse transcriptase inhibitors and protease inhibitors.  
     
     
         13 . The method according to  claim 10  further comprising administering to the subject another pharmaceutical composition.  
     
     
         14 . The method according to  claim 11  further comprising administering to the subject another pharmaceutical composition.  
     
     
         15 . The method according to  claim 12  further comprising administering to the subject another pharmaceutical composition.  
     
     
         16 . The method according to  claim 13  wherein the other pharmaceutical composition comprises an antiviral agent.  
     
     
         17 . The method according to  claim 14  wherein the other pharmaceutical composition comprises an antiviral agent.  
     
     
         18 . The method according  claim 15  wherein the other pharmaceutical composition comprises an antiviral agent.  
     
     
         19 . A pharmaceutical composition for the treatment of a viral infection comprising a first antiviral agent or a pharmaceutically acceptable salt or hydrate thereof, said first antiviral agent comprising a compound or a pharmaceutically acceptable salt or hydrate thereof, said compound of the general formula  
       
         
           
           
               
               
           
         
       
       wherein X and Y are independently selected from the group consisting of O, S, SO, SO 2 , and SO 3 ; wherein n is 0, 1, 2, 3, 4; wherein R, R′ are independently H with the proviso that when R is H, R′ is not H, a C 1 -C 10 , branched or unbranched, substituted or unsubstituted (preferably the substitute is one or more of halogen or CF 3 ), saturated or (poly)unsaturated, (cyclo)alkyl, alkene, alkyn, (cyclo)aryl, aryl(cyclo)alkyl, (cyclo)alkylaryl, alkoxyaryl, alkoxyalkene, alkoxyalkyne, enyne, diene, diyne or alkoxyalkyl, preferably selected from the group consisting of H, CH 3 , CF 3 , CH 2 Cl, CH 2 Br, CH 2 CH 3 , (CH 2 ) 2 CH 3 , (CH 2 ) 3 CH 3 , (CH 2 ) 4 CH 3 , (CH 2 ) 5 CH 3 , (CH 2 ) 6 CH 3 , CH(CH 3 ) 2 , CH(CH 3 ) 3 , CH═C═CH 2 , (CH 2 ) 2 O(CH 2 ) 3 CH 3 , CH 2 HC═CH(CH 2 ) 3 CH 3 , CH 2 C═C(CH 2 ) 3 CH 3 , CH 2 C═C(CH 2 ) 2 CH 3 , CH 2 C═C—CCH 2 CH 3 , CH 2 C═C—CH 3  and CH 2 C═CH and isomers or homologues thereof; and Z is independently selected from the group consisting of R, R′, XR, XR′, YR and YR′ or a functional equivalent thereof.  
     
     
         20 . The pharmaceutical composition of  claim 19  further comprising a second antiviral agent.